FindTrial
Sign In

Mesohepatectomy versus extended hemihepatectomy for centrally located hepatocellular carcinoma: a randomized controlled trial

Mesohepatectomy versus extended hemihepatectomy for centrally located hepatocellular carcinoma: a randomized controlled trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-INR-17013509
Enrollment
Unknown
Registered
2017-11-23
Start date
2017-11-23
Completion date
Unknown
Last updated
2017-11-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular Carcinoma

Interventions

Mesohepatectomy group vs. extended hemi-hepatectomy group:Mesohepatectomy vs. extended hemi-hepatectomy

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Aged 18 to 80 years; 2. Tumors are located in segment IVa, IVb, V or VIII; 3. No intrahepatic metastases and main vascular tumor thrombus; 4. Liver function should be Child-Pugh A; 5. Residual liver volume should=50% functional liver volume.

Exclusion criteria

Exclusion criteria: 1. Non-HCC by pathological examinations; 2. Abodominal surgical history; 3. Patients with TACE history; 4. Patients with other systemic diseases unsuitable for surgery; 5. Pregnant HCC patients; 6. Patients with other malignant diseases; 7. Emergent liver resection for tumor rupture; 8. patients without R0 resection.

Design outcomes

Primary

MeasureTime frame
Overall Survical;—

Countries

China

Contacts

Public ContactWu Hong

Department of Liver Surgery and Liver Transplantation Center, West China Hospital, Sichuan University

Wuhong7801@163.com+86 18980601958

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026